Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations

Kristen R Nichols1, Michael W Demarco2, Michael D Vertin2

  • 1Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Butler University, Indianapolis, Indiana ; Department of Pharmacy, Riley Hospital for Children, Indiana University Health, Indianapolis, Indiana ; Department of Pediatrics, Ryan White Center for Pediatric Infectious Disease, Indiana University School of Medicine, Indianapolis, Indiana. [Dr. DeMarco and Dr. Vertin were students at Butler University at the time of writing.].

Hospital Pharmacy
|January 15, 2014
PubMed

Insights

Vancomycin and piperacillin/tazobactam at specified concentrations formed an initial precipitate upon mixing. This Y-site combination should be considered incompatible for co-infusion in pediatric patients.

Area of Science:

  • Pharmacology
  • Intravenous Drug Compatibility
  • Pediatric Antibiotic Therapy

Background:

  • Vancomycin and piperacillin/tazobactam are frequently used empiric antibiotics in hospitalized children.
  • Existing data on the intravenous (IV) compatibility of these agents at various concentrations are inconsistent.

Purpose of the Study:

  • To assess the Y-site compatibility of vancomycin at 10 mg/mL with piperacillin/tazobactam at 112.5 mg/mL.
  • To provide critical compatibility data for safe co-administration in pediatric care.

Main Methods:

  • Vancomycin (10 mg/mL) and piperacillin/tazobactam (112.5 mg/mL) solutions were prepared and stored refrigerated.
  • Mixtures were visually inspected (color, clarity, particulates) and assessed for pH and turbidity using a Spec-20 turbidimeter.
  • Evaluations were conducted immediately after mixing and at 30 minutes, 1 hour, and 4 hours post-mixing.

Main Results:

  • An immediate, visible milky precipitate formed upon mixing vancomycin and piperacillin/tazobactam.
  • This precipitate dissipated within 15 seconds.
  • No further precipitate was observed, and turbidimetry and pH measurements showed no significant changes from baseline.

Conclusions:

  • The combination of vancomycin 10 mg/mL and piperacillin/tazobactam 112.5 mg/mL exhibits immediate precipitation.
  • Co-infusion via Y-site is not recommended due to observed incompatibility.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
386